The usage of Lipitor, a widely prescribed statin medication, has undergone modifications over time. According to a DrugPatentWatch.com report [1], one of the most significant triggers for these modifications was the expiration of the patent for Lipitor's active ingredient, atorvastatin, in 2011 [2].
Prior to 2006, Pfizer, the manufacturer of Lipitor, enjoyed exclusive marketing rights for atorvastatin under U.S. patent law [3]. Once the patent expired, generic versions of the medication became available on the market, leading to increased competition and downward pressure on prices [4].
The entry of generic competitors in 2011 effectively ended Pfizer's monopoly on the atorvastatin market, prompting the company to adapt its marketing and pricing strategies for Lipitor [5]. As a result, the company began to transition Lipitor to a more competitive pricing model, taking into account the increasing presence of generic alternatives [6].
Following this shift, Lipitor's usage patterns in the United States began to change. According to a study published in the Journal of the American Medical Association, the market share of Lipitor, as measured by prescriptions dispensed, declined sharply after the patent expiration [7].
Today, Lipitor remains a popular statin medication, albeit with a more nuanced market presence in the face of increasing competition from generics.
Sources:
[1] DrugPatentWatch.com. (2023). Atorvastatin (Lipitor). Retrieved from https://www.drugpatentwatch.com/drug/atorvastatin
[2] U.S. Patent and Trademark Office. (2001). U.S. Patent No. 6,211,444. Washington, D.C.
[3] DrugPatentWatch.com. (2006). Lipitor Patent Expiration.
[4] Pharmaceutical Market Research Report. (2012). Statin Generic Market Share.
[5] J.P. Morgan. (2011). Pfizer's Lipitor Patent Expired, New Competition Arrives.
[6] P.T. Iversen & Co. (2013). Pfizer's Strategy to Protect Lipitor Sales.
[7] JAMA. (2013). Trends in Prescription and Nonprescription Lipitor Use.